Human Genome Editing: Our Future Belongs to All of Us
By Françoise Baylis,
Issues in Science and Technology
| 05. 15. 2019
In late November 2018, the Chinese scientist He Jiankui ignited a media firestorm with the birth announcement of “healthy” twin girls, Lulu and Nana (pseudonyms), born following germline genome editing to provide resistance to HIV. This announcement was followed by swift and nearly unanimous condemnation. A common theme among the critics was He’s failure to respect international consensus.
As a strong and steady advocate of “broad societal consensus” as the threshold for ethically acceptable heritable human genome editing, I was intrigued by this response. What is this “consensus” whereof they speak?
A quick review of media reports and various commentaries chastising He for having violated international consensus suggests considerable equivocation about the scope and meaning of consensus. Some commentators referred to a perceived political consensus, others intuited a somewhat amorphous scientific consensus, and a few others complained of a failure to respect the call for broad societal consensus issued in December 2015 at the International Summit on Human Gene Editing.
POLITICAL CONSENSUS
Globally, the political consensus on heritable human genome editing—such as it is—inclines toward an outright ban, and...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...
